Y
Yejinpeng Wang
Researcher at Wuhan University
Publications - 17
Citations - 231
Yejinpeng Wang is an academic researcher from Wuhan University. The author has contributed to research in topics: Germline & Phenotype. The author has an hindex of 6, co-authored 16 publications receiving 107 citations.
Papers
More filters
Journal ArticleDOI
Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer.
Songtao Cheng,Gang Wang,Yejinpeng Wang,Liwei Cai,Kaiyu Qian,Lingao Ju,Xuefeng Liu,Yu Xiao,Xinghuan Wang +8 more
TL;DR: Results suggest that by inhibition of FAO with etomoxir may provide a novel avenue to investigate new therapeutic approaches to human bladder cancer (BCa), and suggest the cell cycle arrest could be reversed by PPARγ antagonist GW9662.
Journal ArticleDOI
Novel Biomarkers Associated With Progression and Prognosis of Bladder Cancer Identified by Co-expression Analysis.
TL;DR: This study screened and confirmed that two biomarkers could accurately predict the progression and prognosis of BC, which is of great significance for both stratification therapy and the mechanism study of BC.
Journal ArticleDOI
Fifteen hub genes associated with progression and prognosis of clear cell renal cell carcinoma identified by coexpression analysis.
Yejinpeng Wang,Liang Chen,Gang Wang,Songtao Cheng,Kaiyu Qian,Xuefeng Liu,Chin-Lee Wu,Yu Xiao,Xinghuan Wang +8 more
TL;DR: It is found that patients of ccRCC with high expression of each hub gene were more likely to have poor prognosis than those with low expression, and by using survival analysis, it is indicated that 15 hub genes have great predictive value for the prognosis and progression ofccRCC.
Journal ArticleDOI
PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells
TL;DR: The results indicated that PPARγ might be crucial for BCa tumorigenesis by interfering with the motility and viability of BCa cells.
Journal ArticleDOI
Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer.
Yejinpeng Wang,Liang Chen,Mengxue Yu,Yayun Fang,Kaiyu Qian,Gang Wang,Lingao Ju,Yu Xiao,Xinghuan Wang +8 more
TL;DR: There is no good prognostic model that could predict the prognosis of bladder cancer (BCa) and the benefit of immunotherapy.